Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis Stefanie Hennig, Karen McKay, Suzanna Vidmar, Katie O'Brien, Sonya Stacey, Joyce Cheney, Claire E. Wainwright Journal of Cystic Fibrosis Volume 13, Issue 4, Pages 428-434 (July 2014) DOI: 10.1016/j.jcf.2014.01.014 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions
Fig. 1 Change in GFR (ml/min) from prior to aminoglycoside exposure (first) to study completion (last). Journal of Cystic Fibrosis 2014 13, 428-434DOI: (10.1016/j.jcf.2014.01.014) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions
Fig. 2 Difference in GFR (glomerular filtration rate) for children exposed to inhaled tobramycin (TOBI®) by duration of the inhaled tobramycin course. Journal of Cystic Fibrosis 2014 13, 428-434DOI: (10.1016/j.jcf.2014.01.014) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions
Fig. 3 Audiogram of child 710 exhibiting a mild hearing loss in the right ear. Journal of Cystic Fibrosis 2014 13, 428-434DOI: (10.1016/j.jcf.2014.01.014) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions